| Literature DB >> 31193099 |
Manish Kumar1,2, Nithya Shanthi1, Arun Kumar Mahato1, Shashank Soni1, P S Rajnikanth2.
Abstract
Superficial fungal infection in immunocompromised patients can lead to many disorders and complications. Currently, new topical treatment options are critically needed to treat these fungal infections. Luliconazole (LZL) is a topical antifungal medicine used for fungal infection treatment. The purpose of this paper was to develop a new topical luliconazole nanocrystal (LNC) incorporated hydrogel. This study suggested the potential benefits of LNC embedded in a gel as a drug delivery system for topical antifungal treatments. Preliminary experiments were therefore carried out to characterize the LNC in comparison with raw drug. Prepared gel was homogeneous for human use with about 88 percent trapping, non-irritant and safe. Nano-systems showed an overall 5 fold enhancement in solubility, 4 fold increase in dissolution velocity, higher skin retention and better antifungal activity. Drugs retained from LNC hydrogel (N-GEL) in different skin layers within 8 h were the highest, i.e. 62.17% compared to coarse suspension (41.87%), nanosuspension (49.77%), D-GEL (55.76%). In addition, LNC and N-GEL had higher ZOI (41.20 ± 0.61mm and 44.25 ± 0.57mm respectively) than LZL and D-GEL (35.98 ± 0.81mm and 36.83 ± 0.83mm respectively). Therefore, it was observed that LNC loaded hydrogel was more effective in killing the fungus. Consequently, hydrogel incorporated with LNC could be a new approach with improved activity and increased dermal delivery for drugs with poor aqueous solubility rather than coarse drug containing gel.Entities:
Keywords: Pharmaceutical science
Year: 2019 PMID: 31193099 PMCID: PMC6517330 DOI: 10.1016/j.heliyon.2019.e01688
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1FTIR Spectra for luliconazole (LZL), Vitamin E TPGS, Physical Mixture of drug and Vitamin E TPGS in 1:1 (PM) and luliconazole nanocrystals (LNC F 19).
Optimization table for speed, solvent and concentration.
| Formulation code | Concentration of Vit. E TPGS (%w/v) | Speed (rpm) | Solvent | Size (μm) | PDI |
|---|---|---|---|---|---|
| F1 | 0.25 | 1000 | Ethanol | 15.3 | 0.238 |
| F2 | 0.25 | Ethanol | 2.795 | 0.350 | |
| F3 | 0.25 | 4000 | Ethanol | 4.996 | 0.815 |
| F4 | 0.25 | 6000 | Ethanol | 18.6 | 1 |
| F5 | 0.25 | 2000 | Propanol | 3.689 | 0.656 |
| F6 | 2000 | 2.272 | 0.287 | ||
| F7 | 2000 | Methanol | 2.312 | 0.312 | |
| F8 | 2000 | Methanol | 2.648 | 0.572 | |
| F9 | 2000 | Methanol | 3.747 | 0.717 | |
| F10 | 2000 | Methanol | 4.064 | 0.853 | |
| F11 | 2 | 2000 | Methanol | 5.727 | 1 |
Effect of temperature control on nanocrystal size.
| Concentration of Vit. E TPGS (%w/v) | Formulation code | Method | Size (μm) | PDI |
|---|---|---|---|---|
| 0.25 | F12 | Nanoprecipitation + Simple Probe Sonication (No temperature control) | 28.96 | 1 |
| F15 | Nanoprecipitation + Cooling Probe Sonication for 15min (temperature controlled) | 0.910 | 1 | |
| 0.5 | F13 | Nanoprecipitation + Simple Probe Sonication (No temperature control) | 16.5 | 1 |
| F16 | Nanoprecipitation + Cooling Probe Sonication for 15min (temperature controlled) | 0.991 | 0.731 | |
| 0.75 | F14 | Nanoprecipitation + Simple Probe Sonication (No temperature control) | 19.3 | 1 |
| F17 | Nanoprecipitation + Cooling Probe Sonication for 15min (temperature controlled) | 1.225 | 0.849 | |
| 0.05 | F 18 | Modified Nanoprecipitation method. | 0.112 | 0.353 |
| 0.1 | F 19 | |||
| 0.25 | F 20 | 0.278 | 0.254 | |
| 0.5 | F 21 | 0.506 | 0.556 | |
| 0.75 | F 22 | 0.611 | 0.772 |
Fig. 3A. X-Ray Diffraction Pattern for luliconazole (LZL), Physical Mixture of LZL and Vit. E TPGS (1:1) and luliconazole nanocrystals (LNC F 19). B. DSC Curve for luliconazole (LZL) and its nanocrystals (LNC F 19). C. Dissolution Study for luliconazole (LZL) and its nanocrystals (LNC F 19).
Effect of Drying on Particle size and PDI.
| Sample | Storage Condition | Size (μm) | PDI |
|---|---|---|---|
| 0.25%w/v Vitamin E TPGS | Room Temp/0 day | 0.278 | 0.254 |
| Room Temp/1 day | 0.289 | 0.253 | |
| Room Temp/1 week | 0.292 | 0.32 | |
| Dried at Room Temp | 0.493 | 0.112 | |
| Oven Dried (40 °C) | 1.438 | 0.316 |
Stability Study for 0.1%w/v Vitamin E TPGS and Combination (0.1%w/v Vitamin E TPGS with 1%w/v HPMC) based Nanocrystals.
| Storage Condition/No of Week Exposed | 0.1%w/v Vitamin E TPGS | |||
|---|---|---|---|---|
| Size (μm)* | PDI* | Zeta* | ||
| Room Temp/0 day | Sample | 0.093 ± 0.11 | -18.36 ± 0.21 | |
| Room Temp/1 day | 0.312 ± 50.08 | 0.120 ± 0.10 | -18.36 ± 0.23 | |
| Room Temp/1 week | 0.94 ± 0.102 | -17.6 ± 0.87 | ||
| 2°C/1 week | 0.358 ± 51.14 | 0.15 ± 0.13 | -17.36 ± 0.40 | |
| 40°C/1 week | 2.571 ± 405.89 | 0.80 ± 0.34 | -1.81 ± 0.08 | |
| Air dried/1 week | 2.038 ± 1115.66 | 0.53 ± 0.40 | -1.81 ± 0.14 | |
| Room Temp/0 day | +1%w/v HPMC | 0.53 ± 0.19 | -19.1 ± 0.21 | |
| Room Temp/1 day | 0.335 ± 39.43 | 0.502 ± 0.49 | -19.1 ± 0.23 | |
| Room Temp/1 week | 0.12 ± 0.072 | -19.07 ± 0.66 | ||
| 2°C/1 week | 0.405 ± 50.20 | 0.76 ± 0.25 | -19.07 ± 0.66 | |
| 40°C/1 week | 0.562 ± 33.24 | 0.26 ± 0.16 | -19.5 ± 0.30 | |
| Air dried/1 week | 0.833 ± 252.54 | 0.44 ± 0.49 | -19.0 ± 0.26 | |
| 40 °C for 1 h and 2 °C for 1h 3 cycle/1 week (thermos-cycling) | 0.664 ± 49.51 | 0.12 ± 0.041 | -18.60 | |
*n=3, mean ± SD.
Fig. 2SEM images for A) luliconazole, B) Vitamin E TPGS based nanocrystals and C) Vitamin E TPGS & 1% HPMC Combination based nanocrystals.
Fig. 4A. Cumulative amount of Drug Permeated. * D-Gel is gel containing luliconazole, N-Gel is gel containing nanocrystals. B. Drug Retention Profile. * D-Gel is LZL Incorporated Gel, N-Gel is LNC Incorporated Gel.